In this first podcast of our series on new technologies, we welcomed back Iscaffpharma by chatting with Per Setterberg, CEO and Professor Göran Landberg, CMO. Göran talks to us about how pre-clinical testing in human tumor microenvironment and synthetic copies of the same adds value to drug screening of oncology drugs. The model creates a pre-clinical fingerprint that mimics the potential effect a drug will have in humans, as well as reduces the need for animal models. Dive in with us as we go in depth into the use of 3D printed scaffolds in cancer drug screening, the ethical considerations behind removing the use of animal models, and what future advances they see in using their technology.
Iscaffpharma is a Bio-Tech company focusing on developing better treatments of aggressive cancers. To learn more about their research and work, check out their publications here.